Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Yale Cancer Center · Philipps University of Marburg · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
141
total citations
- FWCI
- 36.29
- Percentile
- 100%
- References
- 26
Citations per year
Authors
19- LPLajos PusztaiCorresponding
Yale Cancer Center
- CDCarsten Denkert
Philipps University of Marburg
- JOJoyce O’Shaughnessy
Texas Oncology, Baylor University Medical Center, The US Oncology Network
- JCJavier Cortés
Universidad Europea de Madrid
- RDRebecca Dent
National University of Singapore, National Cancer Centre Singapore
Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Oncology
- Event (particle physics)
- Stage (stratigraphy)
- Internal medicine
- Cancer
- Immunotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.